CD40L-Augmented TIL

· H. Lee Moffitt Cancer Center and Research Institute

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for CD40L-Augmented TIL, covering 2026-03-31 to 2026-03-31. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC [Phase 1]